Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice
Neuroimmunomodulation · 2022 · 29 (4) · 359-368
DOI: 10.1159/000521013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroimmunomodulation, online erschienen am 07.02.2022. Verfasst von Hai Duc Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Sunchon, Republi…. Hauptthemen laut MEDLINE: Alzheimer Disease, Diabetes Mellitus, Metformin, Prolactin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Diabetes mellitus (DM) is a risk factor for Alzheimer’s disease (AD). Increasing evidence indicates that the triggering receptor expressed on myeloid cells (TREM)-1 amplifies chronic inflammation, as well as the roles of prolactin (PRL) and metformin (MET) in tau hyperphosphorylation. However, the associations among TREM-1, tau hyperphosphorylation, PRL expression, and MET in DM remain unclear.
Methods
Streptozotocin was used to induce experimental DM in C57BL/6N mice. MET was orally administered at a dose of 400 mg/kg body weight for 6 weeks prior to hippocampal collection in DM mice. Various parameters pertaining to the TREM-1 pathway, tau hyperphosphorylation, PRL, and related factors were analyzed.
Results
Quantitative polymerase chain reaction and Western blot analysis demonstrated that the expression levels of TREM-1, DAP12, casp1, interleukin-1β, Cox2, inducible nitric oxide synthase, pituitary transcriptional factor-1 (Pit-1), and PRL were significantly increased in the hippocampus of DM mice; the expression levels of these pro-inflammatory mediators, PRL receptor (PRLR) short or long (PRLR-S and PRLR-L), and PRL regulatory element-binding (Preb) protein in DM mice treated with MET (DM + MET) were significantly decreased compared with those in control (CON) mice. The levels of p-Tau and glycogen synthase kinase-3 in the DM group were significantly higher than those in the CON group and significantly lower than those in the DM + MET group.
Conclusion
We confirmed the therapeutic potential of MET for both DM and neurodegeneration. Our findings shed new light on the effects of DM on the pathophysiology of AD via the TREM-1 pathway and PRL expression. Thus, an improved understanding of the TREM-1 pathway in hyperglycemic conditions, as well as PRL, Preb, Pit-1, PRLR-L, and PRLR-S gene expression in the liver, brain, and other sites, may help unravel the pathogenesis of insulin resistance and neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Sunchon, Republic of Korea.
- Department of Food and Nutrition, Sunchon National University, Suncheon, Republic of Korea.
- Mokpo Marine Food-Industry Research Center, Mokpo, Jeonam, Republic of Korea.
Zitieren
APA
Duc Nguyen, H., Hoang, N. M. H., Jo, W. H., Ham, J. R., Lee, M. K., & Kim, M. S. (2022). Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice. Neuroimmunomodulation, 29(4), 359-368. https://doi.org/10.1159/000521013
Vancouver
Duc Nguyen H, Hoang NMH, Jo WH, Ham JR, Lee MK, Kim MS. Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice. Neuroimmunomodulation. 2022;29(4):359-368. doi:10.1159/000521013
BibTeX
@article{DucNguyen2022,
author = {Duc Nguyen, Hai and Hoang, Ngoc Minh Hong and Jo, Won Hee and Ham, Ju Ri and Lee, Mi-Kyung and Kim, Min Sun},
title = {Associations among the TREM-1 Pathway, Tau Hyperphosphorylation, Prolactin Expression, and Metformin in Diabetes Mice},
journal = {Neuroimmunomodulation},
year = {2022},
volume = {29},
number = {4},
pages = {359--368},
doi = {10.1159/000521013}
}
EUVIMED